arca was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. arca’s lead development program is intended to be a direct implementation of those ideas. gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (af). arca has identified genetic variations in cardiac receptors that we believe may predict individual patient response to gencaro™, giving gencaro™ the potential to be the first genetically-targeted prevention treatment for af.
Company profile
Ticker
ABIO
Exchange
Website
CEO
Michael Bristow
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
HYSEQ INC, NUVELO INC
SEC CIK
Corporate docs
IRS number
363855489
ABIO stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
23 Apr 24
8-K
Departure of Directors or Certain Officers
4 Apr 24
425
Business combination disclosure
3 Apr 24
8-K
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
3 Apr 24
8-K
Entry into a Material Definitive Agreement
22 Mar 24
8-K
Departure of Directors or Certain Officers
6 Feb 24
8-K
ARCA biopharma Announces 2023 Financial Results
1 Feb 24
10-K
2023 FY
Annual report
1 Feb 24
8-K
Departure of Directors or Certain Officers
31 Jan 24
ARS
2022 FY
Annual report to shareholders
19 Dec 23
Latest ownership filings
SC 13G
Allostery Investments LP
15 Apr 24
SC 13G
JANUS HENDERSON GROUP PLC
11 Apr 24
SC 13G
Avidity Partners Management LP
9 Apr 24
SC 13G/A
Western Standard LLC
5 Apr 24
SC 13D
Adage Capital Management, L.P.
5 Apr 24
SC 13G/A
BML Investment Partners, L.P.
7 Feb 24
4
Jacob Ma-Weaver
31 Jan 24
4
Anders D Hove
31 Jan 24
4
DANIEL J MITCHELL
31 Jan 24
4
James P Flynn
31 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 38.49 mm | 38.49 mm | 38.49 mm | 38.49 mm | 38.49 mm | 38.49 mm |
Cash burn (monthly) | 556.33 k | 454.33 k | 645.67 k | 604.50 k | 556.33 k | 454.33 k |
Cash used (since last report) | 3.80 mm | 3.10 mm | 4.40 mm | 4.12 mm | 3.80 mm | 3.10 mm |
Cash remaining | 34.69 mm | 35.39 mm | 34.08 mm | 34.36 mm | 34.69 mm | 35.39 mm |
Runway (months of cash) | 62.4 | 77.9 | 52.8 | 56.8 | 62.4 | 77.9 |
Institutional ownership, Q2 2023
78.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 27 |
Opened positions | 3 |
Closed positions | 6 |
Increased positions | 2 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 5.67 bn |
Total shares | 11.33 mm |
Total puts | 0.00 |
Total calls | 55.10 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Funicular Fund | 2.58 mm | $5.86 mm |
Jacob Ma-Weaver | 2.58 mm | $6.12 mm |
Funicular Funds | 2.58 mm | $6.40 mm |
BML Investment Partners | 761.86 k | $1.45 mm |
BML Capital Management | 706.93 k | $1.44 bn |
Western Standard | 630.19 k | $1.28 bn |
Vanguard | 461.61 k | $937.08 mm |
Newtyn Management | 313.20 k | $635.80 mm |
BLK Blackrock | 231.96 k | $470.88 mm |
Geode Capital Management | 155.64 k | $315.94 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Jan 24 | Daniel J Mitchell | Stock Option Common Stock | Grant | Acquire A | No | No | 1.64 | 6,000 | 9.84 k | 6,000 |
30 Jan 24 | James P Flynn | Stock Option Common Stock | Grant | Acquire A | No | No | 1.64 | 6,000 | 9.84 k | 6,000 |
30 Jan 24 | Robert E Conway | Stock Option Common Stock | Grant | Acquire A | No | No | 1.64 | 6,000 | 9.84 k | 6,000 |
30 Jan 24 | Grais Linda S | Stock Option Common Stock | Grant | Acquire A | No | No | 1.64 | 6,000 | 9.84 k | 6,000 |
30 Jan 24 | Raymond L. Woosley | Stock Option Common Stock | Grant | Acquire A | No | No | 1.64 | 6,000 | 9.84 k | 6,000 |
News
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
4 Apr 24
Why Flora Growth Shares Are Trading Lower By Around 20%; Here Are 20 Stocks Moving Premarket
4 Apr 24
Nasdaq Gains 75 Points; Acuity Brands Posts Upbeat Earnings
3 Apr 24
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
3 Apr 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
3 Apr 24
Press releases
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WIRE, ABIO, SWAV, MODN
22 Apr 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, AIRC, ABIO, MODN
15 Apr 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ANSS, HRT, CHX, ABIO
10 Apr 24
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of ARCA Biopharma, Inc. - ABIO
9 Apr 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, AIRC, MODN, ABIO
8 Apr 24